Lentiviral vector-mediated overexpression of Klotho in the brain improves Alzheimer's disease-like pathology and cognitive deficits in mice.
Level 5 - mechanism / opinion, no new human data
Preclinical animal model (APP/PS1 mice) and in vitro cell culture study.
PubMed 30851437 · doi:10.1016/j.neurobiolaging.2019.02.003
What was done
Researchers evaluated the therapeutic effects of upregulating Klotho in the brain using 7-month-old amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mice. Animals received an intracerebroventricular injection of a lentiviral vector encoding Klotho (LV-KL) and were assessed three months post-injection for cognitive deficits and Alzheimer's disease-like pathology. Signaling mechanisms involving autophagy activation and protein kinase B (Akt)/mammalian target of rapamycin (mTOR) inhibition were examined in both transgenic mice and BV2 murine microglial cell cultures.
What was found
The abstract reports no numerical data, effect sizes, or exact p-values. Qualitatively, LV-KL significantly induced Klotho overexpression in the brain after three months, ameliorated cognitive deficits, and improved Alzheimer's-like pathology in APP/PS1 mice. In addition, LV-KL induced autophagy activation and Akt/mTOR inhibition in both the mouse model and BV2 microglial cells.
Why it matters
The study suggests that increasing cerebral Klotho expression may enhance autophagic clearance of amyloid-beta via Akt/mTOR inhibition, highlighting Klotho upregulation as an exploratory therapeutic strategy in preclinical Alzheimer's disease research.
Limits
This is strictly preclinical research using transgenic mice and immortalized mouse microglial cells; translation to humans is unproven. The abstract provides no sample sizes, exact quantitative measures, confidence intervals, or safety assessments for intracerebroventricular viral delivery.
Cited by
- supports Alpha-Klotho expression is associated with reduced beta-amyloid plaques in the brain.